Blueprint Medicines Seals $40M Series A
Blueprint Medicines, a company focused on developing personalized, highly-selective cancer therapies, has closed on $40 million in Series A financing. Third Rock Ventures led the round. Proceeds from the financing will be used to develop new cancer therapies, the Cambridge, Mass.-based company said.
11 April 2011•4 mins read
